

Resource Summary Report

Generated by [RRID](#) on Aug 22, 2026

8xGTIIC-luciferase

RRID:Addgene_34615

Type: Plasmid

Proper Citation

RRID:Addgene_34615

Plasmid Information

URL: <http://www.addgene.org/34615>

Proper Citation: RRID:Addgene_34615

Insert Name: synthetic TEAD luciferase reporter

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:21654799](#)

Vector Backbone Description: Backbone Size:4800; Vector Backbone:pGL3b; Vector Types:Luciferase; Bacterial Resistance:Ampicillin

Comments: Addgene sequencing detected a 7 nucleotide insertion at position 107 relative to the author's insert sequence. This results in the loss of a MscI restriction site but does not alter the function of the plasmid. Please click <http://www.addgene.org/34615/notes/> for general advice and technical tips on how to monitor YAP/TAZ regulation and activity in cell culture by 8xGTIIC lux.

Plasmid Name: 8xGTIIC-luciferase

Record Creation Time: 20220422T222147+0000

Record Last Update: 20260815T081354+0000

Ratings and Alerts

No rating or validation information has been found for 8xGTIIC-luciferase.

No alerts have been found for 8xGTIIC-luciferase.

Data and Source Information

Usage and Citation Metrics

We found 226 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Krantz S, et al. (2026) Dissection of G?s and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors. *Cancer research*, 86(4), 940.

Tran PT, et al. (2026) Targeting TYRO3 attenuates apoptotic cell-driven cancer stemness in triple negative breast cancer. *Cell communication and signaling : CCS*, 24(1).

Chen Y, et al. (2026) DPP-Mediated Interaction of TAZ/?-Catenin Promotes the Differentiation of DPSCs into Odontoblasts. *International journal of molecular sciences*, 27(10).

Brown LG, et al. (2026) Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer. *Neoplasia (New York, N.Y.)*, 78, 101321.

Luo C, et al. (2025) Inhibition of Rho GEFs attenuates pulmonary fibrosis through suppressing myofibroblast activation and reprogramming profibrotic macrophages. *Cell death & disease*, 16(1), 278.

Deng N, et al. (2025) Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein. *Breast cancer research : BCR*, 27(1), 63.

Sun Y, et al. (2025) CRB2 depletion induces YAP signaling and disrupts mechanosensing in podocytes. *American journal of physiology. Renal physiology*, 328(4), F578.

El Yousfi Y, et al. (2025) Regulation of ER stress-induced apoptotic and inflammatory responses via YAP/TAZ-mediated control of the TRAIL-R2/DR5 signaling pathway. *Cell death discovery*, 11(1), 42.

Liu C, et al. (2025) Restriction of YWHAB-mediated YAP cytoplasmic retention is a novel mechanism underlying stemness maintenance and chemoresistance in ovarian cancer peritoneal metastasis. *Genes & diseases*, 12(5), 101519.

Shan H, et al. (2025) USP24 promotes hepatocellular carcinoma progression by deubiquitinating and stabilizing YAP1. *Cancer cell international*, 25(1), 164.

Wang Y, et al. (2025) Cytoplasmic TRIM24 promotes colorectal cancer cell proliferation by activating Wnt/?-catenin signaling. *Nature communications*, 16(1), 8598.

Meng F, et al. (2025) SARS-CoV-2 NSP13 interacts with TEAD to suppress Hippo-YAP signaling. *eLife*, 13.

Liu Y, et al. (2025) Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation. *Nature communications*, 16(1), 3583.

Zhang S, et al. (2025) Vertical inhibition of p110 α /AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. *Molecular oncology*, 19(4), 1132.

Dion W, et al. (2025) SON-dependent nuclear speckle rehabilitation alleviates proteinopathies. *Nature communications*, 16(1), 7065.

Wang S, et al. (2025) A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer. *Communications biology*, 8(1), 1278.

Guo S, et al. (2025) VGLL2 and TEAD1 fusion proteins identified in human sarcoma drive YAP/TAZ-independent tumorigenesis by engaging EP300. *eLife*, 13.

Dwyer MB, et al. (2025) The guanine nucleotide exchange factor Ric-8A regulates the sensitivity of constitutively active G α_q to the inhibitor YM-254890. *The Journal of biological chemistry*, 301(5), 108426.

Zhang Z, et al. (2025) YAP/TAZ Inhibitor-Based Drug Delivery System for Selective Tumor Accumulation and Cancer Combination Therapy. *Biomacromolecules*, 26(1), 266.

Sato K, et al. (2025) Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. *Cancer letters*, 612, 217467.